Published in Scand J Haematol on January 01, 1985
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet (2010) 13.59
Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia (2004) 3.59
Infrequent normal B lymphocytes express features of B-chronic lymphocytic leukemia. J Exp Med (1982) 3.25
Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet (1998) 3.07
International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia (2007) 2.96
Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood (2000) 2.92
Exogenous mesenchymal stem cells localize to the kidney by means of CD44 following acute tubular injury. Kidney Int (2007) 2.75
The release of platelet-activating factor from human endothelial cells in culture. J Immunol (1983) 2.41
Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia (2009) 2.24
Mutations in the mu heavy-chain gene in patients with agammaglobulinemia. N Engl J Med (1996) 2.10
ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Ann Oncol (2012) 2.03
Pyrogen retention by highly permeable synthetic membranes during in vitro dialysis. Artif Organs (2001) 2.01
Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia (2000) 1.94
MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation. Leuk Res (1999) 1.90
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse. Leukemia (2004) 1.87
A multicenter international study on the Spinal Cord Independence Measure, version III: Rasch psychometric validation. Spinal Cord (2006) 1.80
Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood (2001) 1.79
CD30 and type 2 T helper (Th2) responses. J Leukoc Biol (1995) 1.72
The angiogenesis induced by HIV-1 tat protein is mediated by the Flk-1/KDR receptor on vascular endothelial cells. Nat Med (1996) 1.72
Role of platelet-activating factor in cardiovascular pathophysiology. Physiol Rev (2000) 1.70
Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia (2004) 1.65
An essential role for BLNK in human B cell development. Science (1999) 1.64
Release of platelet-activating factor (PAF) and histamine. II. The cellular origin of human PAF: monocytes, polymorphonuclear neutrophils and basophils. Immunology (1981) 1.62
A novel monoclonal antibody BI-3C5 recognises myeloblasts and non-B non-T lymphoblasts in acute leukaemias and CGL blast crises, and reacts with immature cells in normal bone marrow. Leuk Res (1985) 1.61
Human liver stem cell-derived microvesicles accelerate hepatic regeneration in hepatectomized rats. J Cell Mol Med (2009) 1.58
Interleukin 1 stimulates platelet-activating factor production in cultured human endothelial cells. J Clin Invest (1986) 1.57
Nephrin redistribution on podocytes is a potential mechanism for proteinuria in patients with primary acquired nephrotic syndrome. Am J Pathol (2001) 1.57
Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia. Ann Hematol (2004) 1.57
Mutations in the human lambda5/14.1 gene result in B cell deficiency and agammaglobulinemia. J Exp Med (1998) 1.55
Antibody-induced redistribution of Heymann antigen on the surface of cultured glomerular visceral epithelial cells: possible role in the pathogenesis of Heymann glomerulonephritis. J Immunol (1985) 1.52
Synthesis and release of platelet-activating factor by human vascular endothelial cells treated with tumor necrosis factor or interleukin 1 alpha. J Biol Chem (1988) 1.52
The molecular action of tumor necrosis factor-alpha. Eur J Biochem (1991) 1.52
PITSLRE protein kinase activity is associated with apoptosis. Mol Cell Biol (1995) 1.51
Exhaled nitric oxide and pulmonary response to iloprost in systemic sclerosis with pulmonary hypertension. Lancet (1998) 1.50
Tumour necrosis factor in serum and synovial fluid of patients with active and severe rheumatoid arthritis. Ann Rheum Dis (1990) 1.50
HIV-1 kills renal tubular epithelial cells in vitro by triggering an apoptotic pathway involving caspase activation and Fas upregulation. J Clin Invest (1998) 1.49
Childhood acute lymphoblastic leukaemia--current status and future perspectives. Lancet Oncol (2001) 1.48
Human endothelial cells are target for platelet-activating factor. I. Platelet-activating factor induces changes in cytoskeleton structures. J Immunol (1987) 1.46
An erythroid specific nuclear factor binding to the proximal CACCC box of the beta-globin gene promoter. Nucleic Acids Res (1988) 1.45
Bone marrow-derived stromal cells prevent apoptotic cell death in B-lineage acute lymphoblastic leukemia. Blood (1992) 1.42
Online clearance measurement in high-efficiency hemodiafiltration. Kidney Int (2007) 1.42
Transgenic mice expressing human CD14 are hypersensitive to lipopolysaccharide. Proc Natl Acad Sci U S A (1993) 1.42
Human B cell development. I. Phenotypic differences of B lymphocytes in the bone marrow and peripheral lymphoid tissue. J Immunol (1985) 1.41
Endocrine pancreatic tumors: factors correlated with survival. Ann Oncol (2005) 1.41
'Role of bone marrow stromal cells in the growth of human multiple myeloma. Blood (1991) 1.40
Cyclosporin A in the treatment of B-chronic lymphocytic leukemia (B-CLL) Leukemia (1994) 1.39
Restoration of gait with orthoses in thoracic paraplegia: a multicentric investigation. Paraplegia (1994) 1.39
PAMELA measurements of cosmic-ray proton and helium spectra. Science (2011) 1.39
"Cytoplasmic" expression of nuclear antigens. Leukemia (1989) 1.38
Vinculin, talin, and integrins are localized at specific adhesion sites of malignant B lymphocytes. Blood (1988) 1.33
IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma. Blood (1998) 1.33
Combination of cladribine and cytarabine is effective for childhood acute myeloid leukemia: results of the St Jude AML97 trial. Leukemia (2009) 1.33
Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method. Cancer Gene Ther (2009) 1.32
Mutations in Igalpha (CD79a) result in a complete block in B-cell development. J Clin Invest (1999) 1.32
Interleukin 3 and interleukin 6 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma. J Exp Med (1989) 1.32
Identification of malignant plasma cell precursors in the bone marrow of multiple myeloma. J Clin Invest (1985) 1.30
Normal equivalent cells of B cell malignancies: analysis with monoclonal antibodies. Br J Haematol (1983) 1.29
Mediators of immune-complex-induced aggregation of polymorphonuclear neutrophils. II. Platelet-activating factor as the effector substance of immune-induced aggregation. Int Arch Allergy Appl Immunol (1981) 1.27
Release of platelet-activating factor and histamine. I. Effect of immune complexes, complement and neutrophils on human and rabbit mastocytes and basophils. Immunology (1977) 1.25
Maternal vascular prostacyclin activity in pre-eclampsia. Lancet (1980) 1.24
Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia. Blood (1996) 1.24
Expression of T-cell receptors TcR1 (gamma/delta) and TcR2 (alpha/beta) in the human intestinal mucosa. Immunology (1989) 1.24
Hyperacute renal allograft rejection in the rabbit. The role of platelet-activating factor and of cationic proteins derived from polymorphonuclear leukocytes and from platelets. Lab Invest (1984) 1.24
The indispensable role of microenvironment in the natural history of low-grade B-cell neoplasms. Adv Cancer Res (2000) 1.22
Depression is the main determinant of quality of life in multiple sclerosis: a classification-regression (CART) study. Disabil Rehabil (2006) 1.22
Interferon gamma inhibits apoptotic cell death in B cell chronic lymphocytic leukemia. J Exp Med (1993) 1.20
Formation of immune deposits and disease. Lab Invest (1986) 1.20
Natural killer cell engineering for cellular therapy of cancer. Tissue Antigens (2011) 1.18
Role of soluble mediators in angiogenesis. Eur J Cancer (1996) 1.17
Tumor necrosis factor alpha-induced angiogenesis depends on in situ platelet-activating factor biosynthesis. J Exp Med (1994) 1.17
Effects of 1,25(OH)2D3 in experimental mesangial proliferative nephritis in rats. Kidney Int (2001) 1.17
Insulin-like growth factor binding protein-3 induces angiogenesis through IGF-I- and SphK1-dependent mechanisms. J Thromb Haemost (2007) 1.16
Alkyl-ether phosphoglycerides influence calcium fluxes into human endothelial cells. J Immunol (1985) 1.16
Adhesion-dependent survival of normal and leukemic human B lymphoblasts on bone marrow stromal cells. Blood (1994) 1.14
Stroma-supported culture in childhood B-lineage acute lymphoblastic leukemia cells predicts treatment outcome. J Clin Invest (1996) 1.14
Reliability of four simple, quantitative tests of balance and mobility in healthy elderly females. Aging (Milano) (1998) 1.14
Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. J Clin Oncol (1996) 1.14
PAF produced by human breast cancer cells promotes migration and proliferation of tumor cells and neo-angiogenesis. Am J Pathol (2000) 1.14
Alternative pathway activation of complement by cultured human proximal tubular epithelial cells. Kidney Int (1994) 1.12
Observational case-control study of the prevalence of chronic cerebrospinal venous insufficiency in multiple sclerosis: results from the CoSMo study. Mult Scler (2013) 1.12
Growth- and differentiation-associated expression of bcl-2 in B-chronic lymphocytic leukemia cells. Blood (1992) 1.11
Potential angiogenic role of platelet-activating factor in human breast cancer. Am J Pathol (1998) 1.11
The ABILHAND questionnaire as a measure of manual ability in chronic stroke patients: Rasch-based validation and relationship to upper limb impairment. Stroke (2001) 1.11
Trunk control test as an early predictor of stroke rehabilitation outcome. Stroke (1997) 1.11
C reactive protein in patients with chronic renal diseases. Ren Fail (2001) 1.10
Potential role of platelet-activating factor in renal pathophysiology. Kidney Int (1986) 1.09